GlaxoSmithKline (GSK) Misses Q4 EPS by 26c
Tweet
Share
E-mail
Get Alerts GSK Hot Sheet
Join SI Premium – FREE
GlaxoSmithKline (NYSE: GSK) reported Q4 EPS of GBP0.23, GBP0.26 worse than the analyst estimate of GBP0.49. Revenue for the quarter came in at GBP8.12 billion versus the consensus estimate of GBP9.86 billion.
For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Starts Arrowhead Pharma (ARWR) at Buy
- U.S. began launching strikes against Iran today - Bloomberg
- Lode Gold plans $7M private placement with Coast Capital follow-on
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
